REGULATION A+ FUNDRAISING VIDEO
CLIENT: INSITU BIOLOGICS, INC.
PRODUCTION COMPANY: DEFCON MEDIA, INC.
DIRECTOR/DP: JAMES HUGHES
PRODUCER: TAYLOR JACKSON
InSitu Biologics, LLC is an emerging drug delivery company focusing on development of new and proprietary treatments using its Matrix™ BioHydrogel. Their lead product, AnestaGel™, is a long-lasting and long-acting non-opiate painkiller, targeted for use in peri-operative regional pain management.
AnestaGel™ uses a novel approach to delivering sustained-released analgesics into the target tissue via the Matrix™ BioHydrogel platform, which is a tunable, biocompatible, and pH neutral platform. This allows AnestaGel™ to provide target site-specific, non-migratory placement, a flexible and high dose drug-load reservoir capacity, and a tunable and predictable pharmacological effect.
InSitu approached Defcon to film and produce a Corporate Overview/Regulation A+ Fundraising video. InSitu needed to create a video that could thoroughly explain what AnestaGel does and the potential impact that it has on the Post-Op & Medical industry. ""
At the beginning of the production with InSitu, we needed to establish our objective and lock down the positioning idea of how we could best showcase how AnestaGel will be showcased to the world. Defcon & InSitu strategized on how to best approach this objective over an hour long phone call to outline they key points that we wanted to get across.
THE OBJECTIVE - SHOW WHY ANESTAGEL IS A DISRUPTER IN THE MEDICAL INDUSTRY
Our objective was to show why AnestaGel is an industry disrupter. We needed to show the medical industry why this Opioid alternative is going to change the the Post-Operative Industry and sits in a category of its own.
THE POSITIONING IDEA - A NON-OPID ALTERNATIVE TO POST-OP PATIENTS
The position idea was that this is a Opioid Post-Operative alternative to reduce the potential risk of patients becoming addicted to opioids after recovering from the surgery.
Our team strategized on how we could best tell InSitu's story and the their industry disrupting post-operative product AnestaGel. Defcon strategized on 3 key takeaways that the viewer will know/feel in being inspired when watching and hearing InSitu's story and mission as a company. We wanted to showcase the benefits and value of why AnestaGel is a game changer.
To begin the production, the CEO of InSitu Biologics flew out to San Diego to sit down with us for the first initial interview. This is where we get a deep understanding of what InSitu Biologics stands for as a company. After a few hours of speaking with Jim the CEO of InSitu, we wrapped our Day 1 shoot and began the pre-production for the second half of the InSitu production.
Our production team flew out to St. Paul, Minnesota to film at the InSitu lab and interview the other co-founders of InSitu. We arrived in St. Paul Monday night and prepared all of the production equipment for Day 2. We arrived at the Heritage Wealth office on a snowy morning in Minnesota to capture the remaining interviews. After a full day of interviewing the InSitu team, we wrapped our Day 1 film shoot.
On our 3rd and final production shoot in Minnesota to wrap the filming on the InSitu fundraising video. We met with the chief of science, Bill Taylor, to interview him about his process of inventing AnestaGel. We met at the InSitu Biologics lab located outside of St. Paul. After we finished interviewing with Bill Taylor, we finished by capturing the process of how they create the AnestaGel.
Using state of the art post-production software our team was able to bring InSitu Biologics story to life.
The final deliverables consisted of a 5:30min and 2:30min Company Overview video to be used in their Regulation A+ Fundraising round. We also captured product photography shots of the AnestaGel application. This content to be used for capital fundraising and various marketing elements including online advertising placement, media partner content, and Instagram marketing.